Current Studies

We use integrated research strategies across multiple disciplines including brain imaging, genomics, public health, and clinical trials with pharmacological agents and behavioral interventions. These clinical studies involve outpatient settings, inpatients, neuroimaging, eating disorders, psychosocial factors, and epidemiology and public health. See below for our active projects.


  • Neuroimaging and CBD for Heroin Use Disorder
  • Predicting medical consequences of novel fentanyl analog overdose using the Toxicology Investigators Consortium (TOXIC)
  • CTN 0099  Emergency Department-INitiated bupreNOrphine and VAlidaTIOn Network Trial (ED-INNOVATION) (NIH HEAL Initiative)
  • CTN 0069 Project ED Health – Opioid Use Disorder in the Emergency Department
  • Strategies To Operationalize the Prevention of Overdose Death (STOP OD)
  • RELAY-Nonfatal Overdose Response System
  • Cannabidiol for Opioid Addiction (IRB Study # 21–00607)
    This is a Phase 2 study to conduct a double-blind (placebo-controlled) randomized controlled trial to evaluate the effects of cannabidiol (CBD) on cue-induced craving and anxiety in individuals with opioid use disorder who are maintained on opioid agonist therapy. In addition to in-lab physiological and behavioral assessments, real-world measures will be monitored with electronic tools over multiple weeks.
    *If you are interested in participating, please call 212-585-4653


  • Endothelial Dysfunction Markers in Cocaine-Dependent Patients Under Recent Abstinence
  • Using Event-Related Potentials to Longitudinally Track Cue-Induced Craving Incubation in Cocaine-Addicted Individuals
  • tDCS to Reduce Craving in Cocaine Addiction


  • NIAAA NCIG-006: Randomized, Double-Blind, Placebo-Controlled Trial Of the Safety and Efficacy of Horizant® (Gabapentin Enacarbil) Extended-Release Tablets For the Treatment of Alcohol Use Disorder


  • The effects of cannabis on human sperm with implications for multigenerational inheritance

Neuroimaging Studies